Who
R. Michael Carruthers
Director
Company insider
Files Form 4 as: Director, OnKure Therapeutics; Chief Financial Officer, Edgewise Therapeutics; Director, Elevation Oncology; Chief Financial Officer, Brickell Biotech; Interim President / CFO, Nivalis Therapeutics.
In numbers
- Trades disclosed
- 60
- Buys
- 1
- Sells
- 6
- Bought
- $50K
- Sold
- $5.1M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 11 Sep 2015
- Last trade
- 7 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,875 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —161,250 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K1,428 at $13.39 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —47,330 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —15,619 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —31,238 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 28 May 2025filed 30 May 2025 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 2 May 2025filed 7 May 2025 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K1,314 at $16.45 | filing |
| 1 May 2025filed 7 May 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,209 at $0.00 | filing |
| 1 May 2025filed 7 May 2025 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,209 at $0.00 | filing |
| 11 Oct 2024filed 16 Oct 2024 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —70,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.